These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 415922)

  • 21. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative experimental evaluation of immunodepressive and toxic effects of L-asparaginase (NSC-109229) from Escherichia coli and from Erwinia carotovora.
    Cavanna M; Celle G; Dodero M; Picciotto A; Pannacciulli I; Brambilla G
    Cancer Treat Rep; 1976 Mar; 60(3):255-7. PubMed ID: 769978
    [No Abstract]   [Full Text] [Related]  

  • 23. Amino acid utilization and urine protein excretion in children treated with succinylated Acinetobacter glutaminase-asparaginase.
    Kien CL; Holcenberg JS
    Cancer Res; 1981 Jun; 41(6):2056-62. PubMed ID: 7016307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical method of cancer control. L-asparaginase in cancer chemotherapy. A review.
    Jayaram HN; Sirsi M
    Indian J Cancer; 1970 Mar; 7(1):71-7. PubMed ID: 4992298
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase I evaluation of succinylated Acinetobacter glutaminase-asparaginase in adults.
    Warrell RP; Chou TC; Gordon C; Tan C; Roberts J; Sternberg SS; Philips FS; Young CW
    Cancer Res; 1980 Dec; 40(12):4546-51. PubMed ID: 7438089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-step purification and kinetic properties of the recombinant L-asparaginase from Erwinia carotovora.
    Krasotkina J; Borisova AA; Gervaziev YV; Sokolov NN
    Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):215-21. PubMed ID: 15032742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antineoplastic activity of L-asparaginase].
    Grgić Z
    Lijec Vjesn; 1969 Jul; 91(7):783-6. PubMed ID: 4910066
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cytostatic effect of L-asparaginase].
    Rakowska-Wódz A; Szyszka K; Abucewicz A
    Wiad Lek; 1970 Jan; 23(2):117-20. PubMed ID: 4985374
    [No Abstract]   [Full Text] [Related]  

  • 29. [Asparaginase and glutaminase activity in Pseudomonas fluorescens in continuous cultivation].
    Eremenko VV; Zhukov AV; Nikolaev AIa
    Mikrobiologiia; 1975; 44(4):615-20. PubMed ID: 809640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asparaginase and glutaminase activities of bacteria.
    Wade HE; Robinson HK; Phillips BW
    J Gen Microbiol; 1971 Dec; 69(3):299-312. PubMed ID: 5004160
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic properties of a new glutaminase-asparaginase preparation and the influence of the lactate dehydrogenase-elevating virus.
    Riley V; Spackman D; Fitzmaurice MA; Roberts J; Holcenberg JS; Dolowy WC
    Cancer Res; 1974 Feb; 34(2):429-38. PubMed ID: 4810909
    [No Abstract]   [Full Text] [Related]  

  • 32. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.
    Holcenberg JS
    Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The toxicity of Escherichia coli L-asparaginase.
    Schein PS; Rakieten N; Gordon BM; Davis RD; Rall DP
    Cancer Res; 1969 Feb; 29(2):426-34. PubMed ID: 4975316
    [No Abstract]   [Full Text] [Related]  

  • 34. Antineoplastic and toxic effects of Acinetobacter and Pseudomonas glutaminase-asparaginases.
    Schmid FA; Roberts J
    Cancer Chemother Rep; 1974; 58(6):829-40. PubMed ID: 4447925
    [No Abstract]   [Full Text] [Related]  

  • 35. Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248.
    Derst C; Henseling J; Röhm KH
    Protein Sci; 2000 Oct; 9(10):2009-17. PubMed ID: 11106175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical significance of L-asparaginase].
    Benkö S
    Orv Hetil; 1969 Aug; 110(35):2019-23. PubMed ID: 4900161
    [No Abstract]   [Full Text] [Related]  

  • 37. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cloning, expression and characterisation of Erwinia carotovora L-asparaginase.
    Kotzia GA; Labrou NE
    J Biotechnol; 2005 Oct; 119(4):309-23. PubMed ID: 15951039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical influence of an enzyme-elevating virus upon long-term remissions of mouse leukemia following asparaginase therapy.
    Riley V; Spackman DH; Fitzmaurice MA
    Recent Results Cancer Res; 1970; 33():81-101. PubMed ID: 4949171
    [No Abstract]   [Full Text] [Related]  

  • 40. Some physicochemical aspects of L-asparaginase therapy.
    Mashburn LT; Landin LM
    Recent Results Cancer Res; 1970; 33():48-63. PubMed ID: 4949169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.